Search
KALA BIO Inc
KALAAdd to Watchlist
0.560USD
-0.039-6.51%
Close 09-22 16:00（ET）
10.83MMarket Cap
LossP/E TTM
KALA Analyst Recommendation Trends
In the current month, KALA has received 0 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. KALA average Analyst price target in the last month is 1.500.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
2
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1
1
1
1
1
2
2
KALA Analyst Rating for Peer Comparison
Updated: Sep 22, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
argenx SE
ARGX
11
14
3
0
0
28
Beigene Ltd
ONC
8
19
0
0
0
27
Ionis Pharmaceuticals Inc
IONS
6
14
6
0
0
26
IQVIA Holdings Inc
IQV
8
12
4
0
0
24
Insmed Inc
INSM
7
17
0
0
0
24
Kymera Therapeutics Inc
KYMR
8
13
2
0
0
23
CRISPR Therapeutics AG
CRSP
4
8
10
0
0
22
Revolution Medicines Inc
RVMD
8
13
1
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Tempus AI Inc
TEM
5
7
7
1
1
21
Financial Forecasting
Based on analysts' estimates, KALA EPS is projected to reach -0.330 in FY2026Q3, following reported EPS of -21.319 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-72.00
-0.30
-0.29
-0.33
-0.32
Actual
0.05
-7.00
-21.32
--
--
Surprise
+100.08%
-2233.33%
-7251.40%
--
--
FAQs
How have KALA BIO IncKALA's recent earnings per share performed?
The market expectation was USD -21.32, while KALA BIO IncKALA's earnings per share (EPS) for the previous quarter was USD -7.00. EPS for the next quarter is expected at USD -0.33.
What is the analyst rating for KALA BIO Inc?
Based on the ratings of KALA BIO Inc's stock from 0 analysts, most analysts support a signal_hold trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as signal_hold. Please note that this is not trading advice. You still need to conduct your own analysis.